FDA Adverse Event Rule Halted At OMB By Administration Regulation Freeze

An FDA proposed rule on reporting postmarketing adverse events is being held up at the Office of Management & Budget while the Bush Administration reviews new and pending regulations.

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Archive

More from Pink Sheet